Notably, TIGIT has demonstrated the capacity to dampen T-cell activation and proliferation, and TIGIT blockade has exhibited encouraging outcomes, resulting in enhanced antitumor immunity and prolonged survival, particularly in glioblastoma [114]. Here, TIGIT is linked to glioblastoma.